← Back to all trials
Not Yet Recruiting
NCT05715801
Hyperbaric Oxygen Therapy Improves Brain Function in Patients With Cognitive Decline After COVID-19 Infection.
Conditions: Cognitive Decline, COVID-19, SARS CoV 2 Infection
Sex: All
Ages: 18 Years – 65 Years
Phase: NA
Enrollment: 80
Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University
Location: China
Summary
COVID-19 has swept the world, and while some people may experience long-term cognitive decline as a result of infection, no effective treatment has been announced.
The primary goal of this study was to determine the efficacy of hyperbaric oxygen therapy in patients with SARS-CoV-2 infection, as well as to assess the effect of hyperbaric oxygen therapy on brain function in patients with COVID-19-related cognitive decline.
In this study, approximately 80 people were randomly assigned to either hyperbaric oxygen or regular oxygen therapy to compare the effects of these two treatments on disease.
Eligibility Criteria
Inclusion Criteria:Out-patients 4 weeks after the diagnosis of SARS-CoV-2 infectionSubjective cognitive decline after SARS-CoV-2 infectionSARS-CoV-2 nucleic acid/antigen test negative.Exclusion Criteria:Contraindications to hyperbaric oxygen therapyCognitive decline can be explained by other diseasesConditions that researchers consider unsuitable for clinical trials.
Source: ClinicalTrials.gov (NCT05715801). StuddyBuddy aggregates publicly available trial information.
